Login
$PTGX
$124.83 +$0.00 (0.0%) After hours

$PTGX SEC Filings

Filed On Filing
06 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to Protagonist

27 Oct 2026 SCHEDULE 13G/A
02 Oct 2026 Form 4: Ali Asif, Chief Financial Officer

Received 58,629 shares by exercise or conversion ($1.39M) · Sold 58,629 shares ($8.31M)

30 Sep 2026 144
10 Sep 2026 Form 4: Patel Dinesh V Ph D, Director

Received 54,174 shares by exercise or conversion ($1.17M) · Sold 54,174 shares ($7.9M) · Received 63,548 shares by exercise or conversion ($1.37M) · 3 more

08 Sep 2026 Form 4: Patel Dinesh V Ph D, Director

Gave 510 shares as a gift

13 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 Form 4: Patel Dinesh V Ph D, Director

Received 65,761 shares by exercise or conversion ($1.42M) · Sold 65,761 shares ($9.81M) · Received 34,239 shares by exercise or conversion ($739K) · 1 more

10 Aug 2026 144
07 Aug 2026 SCHEDULE 13G
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS
05 Aug 2026 S-8 POS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support